Scholarlink

<p>Obesity hypoventilation syndrome is caused by complex interactions between multiple pathological processes, including diminished respiratory drive and sleep-related breathing alterations, leading to structural and functional respiratory impairment and ultimately, pulmonary hypertension. Because pulmonary hypertension is closely associated with obesity hypoventilation syndrome, thoroughly evaluating its etiology is essential, and individualized treatments must be considered. We describe 2 patients with obesity hypoventilation syndrome exhibiting severe pulmonary hypertension with pulmonary vascular resistance exceeding 5 Wood units; both were classified as Group 1 pulmonary hypertension, ie, pulmonary arterial hypertension. Initially admitted to our hospital complaining of dyspnea, both patients commenced pulmonary arterial hypertension therapies in addition to positive airway pressure therapy and diuretics, improving their hemodynamic status, dyspnea, and exercise capacity, and finally enabling their discharge. These findings suggest that pulmonary arterial hypertension can coexist with obesity hypoventilation syndrome, and pulmonary arterial hypertension therapies, introduced with careful consideration, may provide substantial benefits for select patients.</p> Citation: <p>Daigo K, Hiraide T, Momoi M, et&#xa0;al. Pulmonary arterial hypertension therapies in patients with obesity hypoventilation syndrome: a case series. <i>J Clin Sleep Med</i>. 2025;21(4):723–732.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pulmonary arterial hypertension therapies in patients with obesity hypoventilation syndrome: a case series

  • 期刊论文

  • 发表日期：

    2025年4月1日

查看全文
  • Kyohei Daigo,
  • Takahiro Hiraide,
  • Mizuki Momoi,
  • Yoshiki Shinya,
  • Yoshinori Katsumata,
  • Yoshikazu Kishino,
  • Yasuyuki Shiraishi,
  • Takahiko Nishiyama,
  • Shun Kohsaka,
  • Masaki Ieda

摘要

Obesity hypoventilation syndrome is caused by complex interactions between multiple pathological processes, including diminished respiratory drive and sleep-related breathing alterations, leading to structural and functional respiratory impairment and ultimately, pulmonary hypertension. Because pulmonary hypertension is closely associated with obesity hypoventilation syndrome, thoroughly evaluating its etiology is essential, and individualized treatments must be considered. We describe 2 patients with obesity hypoventilation syndrome exhibiting severe pulmonary hypertension with pulmonary vascular resistance exceeding 5 Wood units; both were classified as Group 1 pulmonary hypertension, ie, pulmonary arterial hypertension. Initially admitted to our hospital complaining of dyspnea, both patients commenced pulmonary arterial hypertension therapies in addition to positive airway pressure therapy and diuretics, improving their hemodynamic status, dyspnea, and exercise capacity, and finally enabling their discharge. These findings suggest that pulmonary arterial hypertension can coexist with obesity hypoventilation syndrome, and pulmonary arterial hypertension therapies, introduced with careful consideration, may provide substantial benefits for select patients.

Citation:

Daigo K, Hiraide T, Momoi M, et al. Pulmonary arterial hypertension therapies in patients with obesity hypoventilation syndrome: a case series. J Clin Sleep Med. 2025;21(4):723–732.